Gilead fails to overturn $752m BMS patent verdict
02-04-2020
Kite teams up with Sangamo to treat cancer
26-02-2018
Life sciences companies face off over ‘Juno’ trademark
26-07-2017
Novartis pays Juno $12m in cancer patent licensing deal
07-04-2015
wildpixel / iStockphoto.com
Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Kite, Sloan Kettering Institute, Juno, cancer immunotherapy, US Patent and Trade Office, Patent Trial and Appeal Board, Food and Drug Administration, paten
